Sign in

CIK 0000894158

  • Non-accelerated filer
  • Smaller reporting company

Theriva Biologics, Inc.

Sign in to watch
Ticker
TOVX
Exchange
NYSE
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
NV
Entity type
Operating
EIN
133808303
Phone
+1 734-332-7800
Business address
9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MD, 20850
Former names
Synthetic Biologics, Inc., ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD PHARMACEUTICALS INC, SHEFFIELD MEDICAL TECHNOLOGIES INC
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market buy CEO bought 7,100,679 shares at an average $7.22 ($103,281)
  8. 4 Open-market buy CEO bought 7,094,379 shares at an average $7.13 ($57,025)
  9. 4 Open-market buy CEO bought 7,116,079 shares at an average $6.75 ($200,351)
  10. 4 Open-market buy CEO bought 7,111,379 shares at an average $5.25 ($131,171)
  11. 4/A Open-market buy CEO bought 7,167,379 shares at an average $4.84 ($391,962)
  12. 4 Open-market buy CEO bought 7,167,379 shares at an average $0.72 ($5,139,836)
  13. 4 Open-market buy President bought 10,000 shares at $4.64 ($46,400)
  14. 4 Open-market buy Chief Executive Officer bought 26,500 shares at an average $5.30 ($140,350)
  15. 4 Open-market buy Chief Executive Officer bought 227,000 shares at an average $1.96 ($445,580)
  16. 4 Grant or award Chief Executive Officer acquired 100,000 shares (grant or award)
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 4 Derivatives Options or other derivatives
  20. 4 Grant or award Chief Executive Officer acquired 95,238 shares (grant or award)

Page 7 of 8 · 156 filings